Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia

Dalton Trans. 2007 Nov 21;(43):4893-902. doi: 10.1039/b705989b. Epub 2007 Sep 25.

Abstract

Copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone), Cu-ATSM, labeled with a positron emitting isotope of copper ((60)Cu, (61)Cu, (62)Cu or (64)Cu) has been shown, in vitro and in vivo, to be selective for hypoxic tissue. In silico studies have explored the mechanism of its hypoxia selectivity, and clinical studies with this agent have shown non-invasive imaging data that is predictive of a cancer patients' response to conventional therapy. This Perspective discusses the evolution of Cu-ATSM, how its selectivity can be improved upon, and where this metal-ligand platform could be taken in the future.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Humans
  • Hypoxia / diagnostic imaging*
  • Molecular Structure
  • Neoplasms / diagnostic imaging
  • Neoplasms / therapy
  • Organometallic Compounds* / chemistry
  • Positron-Emission Tomography*
  • Radiopharmaceuticals* / chemistry
  • Thiosemicarbazones* / chemistry

Substances

  • Organometallic Compounds
  • Radiopharmaceuticals
  • Thiosemicarbazones
  • copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)